PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 17, 2026International Dental Journal0 citationsOpen Access

Injection of Adipose-Derived Mesenchymal Stem Cell-Enriched Adipose Extract for Temporomandibular Joint Osteoarthritis: A Randomised Controlled Trial

View Full Paper
BJBingshuai JingZZZerou ZhangYLYaoguang Lv

Key Points

  • This trial aims to evaluate the effectiveness of adipose-derived mesenchymal stem cells versus hyaluronic acid for treating temporomandibular joint osteoarthritis.
  • Randomized controlled trial with 50 patients diagnosed with anterior disc displacement without reduction.
  • Patients received either adipose-derived mesenchymal stem cells-enriched adipose extract (ARDE) or hyaluronic acid injections after joint lavage.
  • Primary outcome measured was Visual Analogue Scale (VAS) scores for pain; secondary outcomes included maximum mouth opening and MRI results.
  • ARDE group showed a greater reduction in VAS score (LS mean change -4.9) compared to HA group (-4.3) with P = .009.
  • Maximum mouth opening improved more in ARDE group (LS mean change 1.7 cm) than HA group (1.4 cm) with P = .022.
  • MRI results indicated a significant improvement in joint effusion in ARDE group (18/22 vs 6/20) with P < .01.

Abstract

AIMS: This study aims to compare the efficacy of adipose-derived mesenchymal stem cells-enriched adipose extract (ARDE) with hyaluronic acid (HA) intra-articular injection in the treatment of temporomandibular joint osteoarthritis. METHODS: The randomised controlled trial included patients who did not respond to conservative treatment, were diagnosed with anterior disc displacement without reduction according to the diagnostic criteria for Temporomandibular Disorders, and had a Visual Analogue Scale (VAS) score >4. After joint lavage, the control group received HA injections, while the study group received ARDE injections. The primary outcome included VAS scores for pain, while secondary outcome measures included maximum mouth opening (MMO) and magnetic resonance imaging results. Evaluations were performed at baseline, 1 month, and 6 months postoperatively. RESULTS: A total of 50 patients were enrolled (25 per group), with comparable baseline characteristics between groups (P > .05). Analysis of covariance showed that the least-squares (LS) mean change in VAS score from baseline to month 6 in the ARDE vs HA groups was -4.9 vs -4.3 cm, respectively (LS mean difference, -0.7; 95% CI, -1.1 to -0.2; P = .009). For the MMO, the LS mean change was 1.7 vs 1.4 cm, respectively (LS mean difference, 0.3; 95% CI, 0 to 0.5; P = .022). Linear mixed-effects models verified significant group and time main effects for VAS score (both P .05). Magnetic resonance imaging indicated more significant resolution of preoperative joint effusion in ARDE group (18/22 vs 6/20, P < .01). CONCLUSION: ARDE injections demonstrate promising potential in relieving pain and improving joint function in patients with temporomandibular joint osteoarthritis, as compared with HA injections.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jing et al. (2026) studied this question.

synapsesocial.com/papers/6a095a877880e6d24efe0838https://doi.org/10.1016/j.identj.2026.109604
Ask AI
Helpful
Bookmark
Share
View Full Paper